BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li F, Li Q, Liu Y, Han J, Zheng W, Huang Y, Zheng X, Cao L, Zhou J. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol 2020;30:461-70. [DOI: 10.1007/s00330-019-06317-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Granata V, Fusco R, Belli A, Borzillo V, Palumbo P, Bruno F, Grassi R, Ottaiano A, Nasti G, Pilone V, Petrillo A, Izzo F. Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect Agents Cancer 2022;17. [DOI: 10.1186/s13027-022-00429-z] [Reference Citation Analysis]
2 Chen J, Zhu J, Zhang C, Song Y, Huang P. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. Eur Radiol 2020;30:2871-80. [PMID: 32020403 DOI: 10.1007/s00330-019-06649-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Fraum TJ, Cannella R, Ludwig DR, Tsai R, Naeem M, Leblanc M, Salter A, Tsung A, Shetty AS, Borhani AA, Furlan A, Fowler KJ. Assessment of primary liver carcinomas other than hepatocellular carcinoma (HCC) with LI-RADS v2018: comparison of the LI-RADS target population to patients without LI-RADS-defined HCC risk factors. Eur Radiol 2020;30:996-1007. [DOI: 10.1007/s00330-019-06448-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Lv K, Cao X, Dong Y, Geng D, Zhang J. CT/MRI LI-RADS version 2018 versus CEUS LI-RADS version 2017 in the diagnosis of primary hepatic nodules in patients with high-risk hepatocellular carcinoma. Ann Transl Med 2021;9:1076. [PMID: 34422988 DOI: 10.21037/atm-21-1035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021;15:1267-79. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Reference Citation Analysis]
6 Xu X, Mao Y, Tang Y, Liu Y, Xue C, Yue Q, Liu Q, Wang J, Yin Y, Yang J. Classification of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Based on Radiomic Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/5334095] [Reference Citation Analysis]
7 Spann S, Fetzer DT. Contrast-Enhanced Ultrasound in Chronic Liver Diseases. Magn Reson Imaging Clin N Am 2021;29:291-304. [PMID: 34243918 DOI: 10.1016/j.mric.2021.05.006] [Reference Citation Analysis]
8 Zuo D, Yang K, Wu S. Diagnostic performance of intravascular perfusion based contrast-enhanced ultrasound LI-RADS in the evaluation of hepatocellular carcinoma. Clin Hemorheol Microcirc 2021. [PMID: 33867358 DOI: 10.3233/CH-211164] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hu YX, Shen JX, Han J, Mao SY, Mao RS, Li Q, Li F, Guo ZX, Zhou JH. Diagnosis of Non-Hepatocellular Carcinoma Malignancies in Patients With Risks for Hepatocellular Carcinoma: CEUS LI-RADS Versus CT/MRI LI-RADS. Front Oncol 2021;11:641195. [PMID: 33912456 DOI: 10.3389/fonc.2021.641195] [Reference Citation Analysis]
10 Fan PL, Ding H, Mao F, Chen LL, Dong Y, Wang WP. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics. Eur J Radiol 2020;132:109341. [PMID: 33069987 DOI: 10.1016/j.ejrad.2020.109341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Li J, Yang L, Ma L, Lu Q, Luo Y. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis. Ultraschall Med 2021;42:187-93. [PMID: 33307595 DOI: 10.1055/a-1309-1568] [Reference Citation Analysis]
12 Li L, Hu Y, Han J, Li Q, Peng C, Zhou J. Clinical Application of Liver Imaging Reporting and Data System for Characterizing Liver Neoplasms: A Meta-Analysis. Diagnostics (Basel) 2021;11:323. [PMID: 33671158 DOI: 10.3390/diagnostics11020323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Zeng D, Xu M, Liang JY, Cheng MQ, Huang H, Pan JM, Huang Y, Tong WJ, Xie XY, Lu MD, Kuang M, Chen LD, Hu HT, Wang W. Using new criteria to improve the differentiation between HCC and non-HCC malignancies: clinical practice and discussion in CEUS LI-RADS 2017. Radiol Med 2021. [PMID: 34665430 DOI: 10.1007/s11547-021-01417-w] [Reference Citation Analysis]
14 Guo HL, Zheng X, Cheng MQ, Zeng D, Huang H, Xie XY, Lu MD, Kuang M, Wang W, Xian MF, Chen LD. Contrast-Enhanced Ultrasound for Differentiation Between Poorly Differentiated Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Ultrasound Med 2021. [PMID: 34423864 DOI: 10.1002/jum.15812] [Reference Citation Analysis]
15 Chen Y, Wang W. Differentiation between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced ultrasound: A systematic review and meta-analysis. Clin Hemorheol Microcirc 2021. [PMID: 33935070 DOI: 10.3233/CH-211145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Huang JY, Li JW, Ling WW, Li T, Luo Y, Liu JB, Lu Q. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma? World J Gastroenterol 2020; 26(27): 3938-3951 [PMID: 32774068 DOI: 10.3748/wjg.v26.i27.3938] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
17 Guo HL, Lu XZ, Hu HT, Ruan SM, Zheng X, Xie XY, Lu MD, Kuang M, Shen SL, Chen LD, Wang W. Contrast-Enhanced Ultrasound-Based Nomogram: A Potential Predictor of Individually Postoperative Early Recurrence for Patients With Combined Hepatocellular-Cholangiocarcinoma. J Ultrasound Med 2021. [PMID: 34751450 DOI: 10.1002/jum.15869] [Reference Citation Analysis]
18 Yang J, Huang JY, Chen X, Ling WW, Luo Y, Shi YJ, Liu JB, Lu Q, Lyshchik A. Combined hepatocellular-cholangiocarcinoma: can we use contrast-enhanced ultrasound Liver Imaging Reporting and Data System (LI-RADS) to predict the patient's survival? Eur Radiol 2021;31:6397-405. [PMID: 33492470 DOI: 10.1007/s00330-020-07656-1] [Reference Citation Analysis]
19 Ding J, Qin Z, Zhou Y, Zhou H, Zhang Q, Wang Y, Jing X, Wang F. Impact of Revision of the LR-M Criteria on the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS. Ultrasound Med Biol 2021;47:3403-10. [PMID: 34598799 DOI: 10.1016/j.ultrasmedbio.2021.08.007] [Reference Citation Analysis]
20 Zheng W, Li Q, Zou XB, Wang JW, Han F, Li F, Huang LS, Li AH, Zhou JH. Evaluation of Contrast-enhanced US LI-RADS version 2017: Application on 2020 Liver Nodules in Patients with Hepatitis B Infection. Radiology. 2020;294:299-307. [PMID: 31769742 DOI: 10.1148/radiol.2019190878] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
21 Ding J, Long L, Zhang X, Chen C, Zhou H, Zhou Y, Wang Y, Jing X, Ye Z, Wang F. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol 2021;31:847-54. [PMID: 32803416 DOI: 10.1007/s00330-020-07159-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cheng MQ, Hu HT, Huang H, Pan JM, Xian MF, Huang Y, Kuang M, Xie XY, Li W, Wang W, Lu MD. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade. Eur Radiol 2021;31:5680-8. [PMID: 33502556 DOI: 10.1007/s00330-020-07660-5] [Reference Citation Analysis]